Global Biosimilar and Biologics Market Growth 2024-2030

Global Biosimilar and Biologics Market Growth 2024-2030

The global Biosimilar and Biologics market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Biosimilar and Biologics Industry Forecast” looks at past sales and reviews total world Biosimilar and Biologics sales in 2023, providing a comprehensive analysis by region and market sector of projected Biosimilar and Biologics sales for 2024 through 2030. With Biosimilar and Biologics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biosimilar and Biologics industry.

This Insight Report provides a comprehensive analysis of the global Biosimilar and Biologics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biosimilar and Biologics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biosimilar and Biologics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilar and Biologics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilar and Biologics.

United States market for Biosimilar and Biologics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Biosimilar and Biologics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Biosimilar and Biologics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Biosimilar and Biologics players cover Pfizer, Roche AG, AbbVie, Novartis AG and Merck, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar and Biologics market by product type, application, key manufacturers and key regions and countries.

Segmentation by type
Monoclonal Antibody
Vaccines
Recombinant Insulin
Growth Factors
Immune Modulators
Fusion Protein
Erythoprotein
Other

Segmentation by application
Autoimmune Diseases
Infectious Diseases
Cardiovascular Disorders
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Roche AG
AbbVie
Novartis AG
Merck
Bristol Myers Squibb
GSK
AstraZeneca
Eli Lilly
Bayer
Gilead Sciences
Amgen
Boehringer Ingelheim
Novo Nordisk
Viatris
Johnson
Sanofi Winthrop Industries
Serum Institute of India
Biocon
Intas Pharmaceuticals

Key Questions Addressed in this Report

What is the 10-year outlook for the global Biosimilar and Biologics market?

What factors are driving Biosimilar and Biologics market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Biosimilar and Biologics market opportunities vary by end market size?

How does Biosimilar and Biologics break out type, application?

Please note: The report will take approximately 2 business days to prepare and deliver.